Source: International Congress 2017 – Bronchiectasis and NTM infections: epidemiology, phenotyping and therapeutic strategies
Disease area: Airway diseases, Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
E. Garcia Cortacero (Granada, Spain). Adherence in bronchiectasis (BQ) and concordance between multidimensional scales in a cohort of patients colonized by Pseudomonas aeruginosa (PsA).. 4070

Member's Comments

No comment yet.

Related content which might interest you: Reduction of the cost associated with exacerbations after treatment with nebulized sodium colistimethate (Promixin®) in patients with bronchiectasis (BQ) and chronic bronchial infection (CBI) with Pseudomonas aeruginosa (PsA). Source: International Congress 2017 – Clinical update on bronchiectasis and nontuberculous mycobacteria (NTM) infections Year: 2017 Robustness of assessment of pulmonary endpoints in phase 3 trials with ARD-3150 in non-cystic fibrosis bronchiectasis (NCFB) patients with chronic Pseudomonas aeruginosa (PA) infections Source: International Congress 2018 – Improving the quality of life of patients with bronchiectasis Year: 2018 DNA fingerprinting of Pseudomonas aeruginosa (Pa) in cystic fibrosis patients: risk assessment of cross-colonisation in a CF revalidation centre Source: Eur Respir J 2002; 20: Suppl. 38, 208s Year: 2002 Effect of prior year pulmonary exacerbation (PE) frequency on response to ARD-3150 in patients with non-cystic fibrosis bronchiectasis (NCFB) chronically infected with Pseudomonas aeruginosa (PA) Source: International Congress 2018 – Improving the quality of life of patients with bronchiectasis Year: 2018 Serial measures of airway function in infants & preschoolers with cystic fibrosis (CF) according to pseudomonas aeruginosa (PsA) status Source: Eur Respir J 2007; 30: Suppl. 51, 449s Year: 2007 Late Breaking Abstract - Reduction in frequency of pulmonary exacerbations (PE) with inhaled ARD-3150 in non-cystic fibrosis bronchiectasis (NCFB) patients is independent of Pseudomonas aeruginosa (PA) susceptibility at baseline Source: International Congress 2017 – Update on community acquired pneumonia Year: 2017 Pseudomonas aeruginosa in patients hospitalised for COPD exacerbation: a prospective study Source: Eur Respir J 2009; 34: 1072-1078 Year: 2009 A randomised comparison of two tobramycin formulations in cystic fibrosis (CF) patients with chronic pseudomonas aeruginosa (PA) infection for pharmacokinetic and therapeutic equivalence Source: Annual Congress 2013 –Cystic fibrosis: basic and applied science Year: 2013 Persistence and genetic adaptation of Pseudomonas aeruginosa in patients with COPD. Source: Virtual Congress 2020 – Airway infection: the microbiome and beyond Year: 2020 Assessment of health-related quality of life in patients with bronchiectasis colonized by Pseudomonas aeruginosa Source: Virtual Congress 2021 – Bronchiectasis and pleural infection Year: 2021 Survey of Pseudomonas aeruginosa genotypes in colonised cystic fibrosis patients Source: Eur Respir J 2006 Oct 01;28(4):740-747 Year: 2006 Influence of biofim on the bronchial microbiome in COPD patients colonized or infected by pseudomonas aeruginosa Source: International Congress 2015 – Advances from translational research in respiratory infections Year: 2015 Change in the susceptibility pattern of Streptococcus pneumoniae (SP) and risk factors (RF) for antibiotic resistance (AR) in patients with community-acquired pneumonia (CAP) Source: Eur Respir J 2003; 22: Suppl. 45, 546s Year: 2003 Newly acquired pseudomonas aeruginosa (P.a.) in Belgian CF-patients: does the patients‘ P.a. genotype correlate with environmental genotypes? Source: Annual Congress 2004 - Cystic fibrosis in the 21st century: cutting edge investigations, taxing problems Year: 2004 Pseudomonas aeruginosa colonisation in patients without bronchiectasis Source: International Congress 2014 – Clinical management of lung diseases: from bronchi to pleura Year: 2014 An experience of moxifloxacin (MOX) use in therapy of nosocomial pneumonia (NP) in patients who hadn‘t risk factors to be infected by Pseudomonas aeruginosa Source: Eur Respir J 2005; 26: Suppl. 49, 187s Year: 2005 A randomised placebo-controlled dose finding study of tobramycin inhalation powder (TIP) in patients with bronchiectasis (BE) and pulmonary P. aeruginosa Pa) infection (iBEST-1) Source: International Congress 2018 – Improving the quality of life of patients with bronchiectasis Year: 2018 Colonisation in stable patients with COPD: results of an Italian epidemiological study (PRIME study) Source: Annual Congress 2005 - Acute and chronic infections in COPD Year: 2005 Lung function, symptoms and inflammatory biomarkers in patients with bronchiectasis (brx) with and without chronic pseudomonas aeruginosa (psa) colonisation Source: Annual Congress 2009 - Translational research/biomarkers Year: 2009 Prevalence of relevant multi-drug resistant (MDR) pathogens in a bronchiectasis (BE) cohort. Source: International Congress 2019 – Complex respiratory infections in clinical practice Year: 2019